TLyp-1-modified exosome–mediated delivery of circRAPGEF5 ASO inhibits lung adenocarcinoma metastasis via regulating the miR-570-3p/SPP1 axis
Quick Facts
- Publication title: TLyp-1-modified exosome–mediated delivery of circRAPGEF5 ASO inhibits lung adenocarcinoma metastasis via regulating the miR-570-3p/SPP1 axis
- Journal: Mater Today Bio
- Year: 2025
- DOI: 10.1016/j.mtbio.2025.102416
- PMID/PMCID: 41209704; PMC12593693
Research overview
This study clarified the mechanism of tLyp-1-EXO-circRAPGEF5 ASO in inhibiting LUAD metastasis, indicating that circRAPGEF5 may serve as a new intervention target for LUAD metastasis. Consequently, using engineered exosomal preparations of circular RNAs for delivery into tumor cells represents a safe and effective strategy for cancer treatment.
Key findings
Exosome circRAPGEF5 promotes lung adenocarcinoma (LUAD) metastasis and may serve as an intervention target, but its mechanism of action is unclear.
Consequently, using engineered exosomal preparations of circular RNAs for delivery into tumor cells represents a safe and effective strategy for cancer treatment.
The results confirmed the successful construction of tLyp-1-exosome (EXO)-circRAPGEF5 antisense oligonucleotides (ASO).
tLyp-1 modified exosomes efficiently targeted LUAD tumors in vivo and in vitro.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, cargo loading.
Related platforms: Exoomics®, Echosome®
Related services and capabilities: EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), Small RNA / Cargo Loading
References
Original publication: TLyp-1-modified exosome–mediated delivery of circRAPGEF5 ASO inhibits lung adenocarcinoma metastasis via regulating the miR-570-3p/SPP1 axis Materials Today Bio. 2025. DOI: 10.1016/j.mtbio.2025.102416. PMID/PMCID: 41209704; PMC12593693.